Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Kintara Therapeutics
Pharma pays $100m up front and makes $20m equity investment for rights to three preclinical cancer programs. Plus more than 20 deal summaries, including COVID-19-related transactions.
Once expected to be absorbed by Sanofi, US biotech Warp Drive Bio now will become part of California’s Revolution Medicines in a stock transaction. Sosei elects against its option to acquire MiNA Therapeutics; MeiraGTX follows its June IPO with takeout of Vector Neurosciences. Other recent mergers and acquisitions...
Appointments: News From Sensei, DelMar, Seattle Genetics, Astellas, Galecto, Roivant Sciences And PDL BioPharma
This week's announcements include new CEOs at Sensei and DelMar, new chief medical officers at Seattle Genetics, Astellas Pharma, Galecto Biotech and Roivant Sciences, and new business development heads at Roivant and PDL BioPharma.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in September 2017.
- Other Names / Subsidiaries
- Adgero Biopharmaceuticals Holdings, Inc.
- DelMar Pharmaceuticals, Inc.